Skip to content
Briviact, Briviact (in italy: nubriveo)(brivaracetam)
Briviact (brivaracetam) is a small molecule pharmaceutical. Brivaracetam was first approved as Briviact (in italy: nubriveo) on 2016-01-13. It is used to treat seizures in the USA. It has been approved in Europe to treat epilepsy. The pharmaceutical is active against synaptic vesicle glycoprotein 2A.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Briviact (generic drugs available since 2022-06-09)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Brivaracetam
Tradename
Company
Number
Date
Products
BRIVIACTUCBN-205836 RX2016-05-12
5 products, RLD, RS
BRIVIACTUCBN-205837 RX2016-05-12
1 products, RLD, RS
BRIVIACTUCBN-205838 RX2016-05-12
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
briviactNew Drug Application2021-04-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
seizuresHP_0007359D012640G40.4
Agency Specific
FDA
EMA
Expiration
Code
BRIVARACETAM, BRIVIACT, UCB INC
2024-08-27NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Brivaracetam, Briviact, Ucb Inc
107296532030-04-09DP
69114612026-02-21DS, DPU-1815, U-2130, U-2295
ATC Codes
N: Nervous system drugs
— N03: Antiepileptics
— N03A: Antiepileptics
— N03AX: Other antiepileptics in atc
— N03AX23: Brivaracetam
HCPCS
No data
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
EpilepsyD004827EFO_0000474G40.93518—329
SeizuresD012640G40.4114——5
Absence epilepsyD004832G40.A——2——2
Spinal cord injuriesD013119EFO_1001919111——2
Unverricht-lundborg syndromeD020194Orphanet_308G40.3——1——1
NeuralgiaD009437EFO_0009430——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Partial epilepsiesD004828EFO_0004263—1———1
Postherpetic neuralgiaD051474—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—5————5
Brain neoplasmsD001932EFO_0003833C711————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast feedingD001942————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBRIVARACETAM
INNbrivaracetam
Description
Brivaracetam is a non-proteinogenic amino acid derivative that is butanamide in which the pro-S hydrogen at position 2 is replaced by a (4R)-2-oxo-4-propylpyrrolidin-1-yl. Used for treatment of partial onset seizures related to epilepsy. It has a role as an anticonvulsant. It is a gamma-lactam and a non-proteinogenic amino acid derivative. It is functionally related to a L-alpha-aminobutyric acid.
Classification
Small molecule
Drug classnootropic agents (learning, cognitive enhancers), piracetam type
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1
Identifiers
PDB—
CAS-ID357336-20-0
RxCUI1739745
ChEMBL IDCHEMBL607400
ChEBI ID—
PubChem CID9837243
DrugBankDB05541
UNII IDU863JGG2IA (ChemIDplus, GSRS)
Target
Agency Approved
SV2A
SV2A
Organism
Homo sapiens
Gene name
SV2A
Gene synonyms
KIAA0736
NCBI Gene ID
9900
Protein name
synaptic vesicle glycoprotein 2A
Protein synonyms
solute carrier family 22 member B1
Uniprot ID
Q7L0J3
Mouse ortholog
Sv2a (64051)
synaptic vesicle glycoprotein 2A (Q9JIS5)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 879 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,915 adverse events reported
View more details